There are a wide variety of medications available to relieve the symptoms of various mental health conditions, some of which act on specific neurotransmitters and increase their levels in the brain.

Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026.

The locus coeruleus (LC) is a small region of the brainstem that produces norepinephrine, a chemical with powerful effects on arousal and wakefulness which plays an important role in the body's ...

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has ...

Baxter International Inc. BAX recently announced the receipt of the FDA's approval and commercial launch of premix (ready-to-use) Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine).

Researchers at the University of Pennsylvania School of Medicine have found that the neurotransmitter norepinephrine is essential in retrieving certain types of memories. This represents the first ...

To examine how two vasopressors used in acute traumatic spinal cord injury (SCI) affect intrathecal cerebrospinal fluid pressure and the corresponding spinal cord perfusion pressure (SCPP). Acute SCI ...

In total, 67 patients were included in the final analysis (Fig. 1). All data were expressed as means ± standard deviations or medians [interquartile ranges]. There was no difference in the demographic ...

Long Grove Pharmaceuticals announced the strategic in-licensing of norepinephrine in 0.9% sodium chloride premix formulation from Nevakar Injectables. This manufactured, ready-to-use formulation is ...